SLN:NASDAQSilence Therapeutics Plc - American Depository Share Analysis

Silence Therapeutics (SLN) is trading at $11.55, comfortably above its 20‑day SMA of $10.61, 50‑day SMA of $8.55 and 200‑day SMA of $6.79, confirming a strong bullish bias. Technicals show a bullish MACD crossover (MACD line > signal line) and an RSI around 62, indicating momentum without being overbought. The price sits near the $12.19 resistance with support at $8.91, while volatility is extreme (≈98% 30‑day) and beta exceeds 1.5, implying large price swings; the market sentiment index reads “Extreme Greed” and the model projects a 152% upside/downside potential.
Fundamentally, the company is loss‑making with negative operating and net margins, a high price‑to‑book of 11× and a price‑to‑sales ratio above 650×, reflecting severe valuation compression relative to earnings. However, the siRNA pipeline (e.g., SLN124, SLN360) has attracted analyst attention, leading to an “Overweight” initiation and a buy recommendation despite the cash‑flow deficit. Recent share‑price surge on higher‑than‑average volume suggests short‑term enthusiasm, but earnings‑estimate revisions may not sustain further gains without clinical milestones.